News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

Ergebnisse Phase 2 Bauchspeicheldrüsenkrebs: https://immunitybio.com/immunitybio-announces-results-of-phase-2-metastatic-pancreatic-cancer-trial-at-asco-gi-with-median-overall-survival-of-6-3-months-in-patients-with-third-line-disease-more-than-doubling-historical-sur/

Covid-19 manufacturing roundup: NY biotech primed to become ImmunityBio's drug substance goldmine; Illinois set to meet demand for at-home tests https://endpts.com/covid-19-manufacturing-roundup-ny-biotech-primed-to-become-immunitybios-drug-substance-goldmine-illinois-set-to-meet-demand-for-at-home-tests/

Over 400,000 square foot, state-of-the-art, finish-fill and lyophilization facility enables one billion doses of RNA and adjuvant vaccine production Newly constructed Current Good Manufacturing Practices (cGMP) facility with clean rooms will expedite capabilities for large-scale manufacture of self-amplifying RNA and second-generation DNA COVID-19 vaccine platforms, as well as immunotherapy product candidates ImmunityBio’s cGMP cell therapy, fusion protein, and vaccine biological manufacturing plants now span the globe enabling vertically integrated, commercial-scale manufacturing capacity

ImmunityBio Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic Response and Preparedness https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-expands-manufacturing-capacity-state-art?field_nir_news_date_value[min]=

Soon-Shiong Pours Another $300M Into ImmunityBio https://labusinessjournal.com/news/2022/jan/10/soon-shiong-pours-another-300m-immunitybio/

Amyris and ImmunityBio surge after announcing completion of JV https://seekingalpha.com/amp/news/3784653-amyris-and-immunitybio-surge-after-announcing-completion-of-jv

ImmunityBio Awarded Seminal Patent on Natural Killer Cells https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-awarded-seminal-patent-natural-killer-cells?field_nir_news_date_value[min]=

Amyris and Immunitybio Complete Joint Venture for Next Generation Covid-19 RNA Vaccine https://ir.immunitybio.com/news-releases/news-release-details/amyris-and-immunitybio-complete-joint-venture-next-generation?field_nir_news_date_value[min]=

Dr. Pat Soon-Shiong @DrPatSoonShiong 19 hours ago: The old style Newsaper still lives on..for some. WSJ article on New Year’s Eve now 2 years since COVID ..”while antibodies block, T cells attack and kill cells that are infected”. We have said this over and over and over .. the next generation vaccine to stop transmission ⁦

ImmunityBio, Inc. @ImmunityBio 1 hour ago: Important findings as we start the New Year: A pair of separate studies—from the Netherlands and South Africa—have found that T cells mobilized by vaccination reduce the severity of the disease. https://www.wsj.com/articles/the-t-cell-covid-cavalry-antibodies-vaccines-omicron-11640906490

Harry Reid ist verstorben. https://amp.cnn.com/cnn/2021/12/28/politics/harry-reid-dies/index.html

ImmunityBio pares gains following aldoxorubicin data in cancer https://seekingalpha.com/amp/news/3783723-immunitybio-pares-gains-following-aldoxorubicin-data-in-cancer

Ein weiterer Seeking Alpha Artikel https://seekingalpha.com/article/4476969-immunitybio-company-leaves-2021-on-a-high-note-share-price-still-falls-flat?source=copy_to_clipboard

https://www.google.com/amp/s/seekingalpha.com/amp/article/4472560-amyris-vaccine-upside Summary Amyris is the only synthetic biology company developing and manufacturing a portfolio of products at scale. Amyris has obtained access to differentiated vaccine technology through a licensing arrangement with the Infectious Disease Research Institute. Amyris has also partnered with ImmunityBio to gain access to RNA manufacturing capacity. ImmunityBio is developing COVID vaccines that have the potential to provide broader and longer lasting protection. Amyris is currently undervalued, even without considering the potential upside from a differentiated COVID vaccine.

CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer https://www.businesswire.com/news/home/20211221005233/en/CytRx-Highlights-ImmunityBios-Use-of-Aldoxorubicin-in-Ongoing-Clinical-Studies-for-Various-Forms-of-Cancer